IPF is a rare orphan disease affecting approximately 100,000 U.S. patients. There is no known cure and the mean survival rate is 3 years after diagnosis.
Our drug premise: An antibody therapeutic that binds to and blocks the activity of the calcium activated potassium channel KCa3.1. TetraGenetics has discovered several antibodies that modulate this channel. KCa3.1 is believed to play a critical role in TGFβ1-dependent fibrotic responses in human lung tissues and inhibition of the channel has been shown to significantly attenuate pro-fibrotic response. The high specificity of our antibody is expected to enable selective binding to the target, block the calcium flow and thwart the growth of fibrous lung tissue.